These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23982649)

  • 1. The feasibility of delivering a duodenal-jejunal bypass liner (EndoBarrier) endoscopically with patients under conscious sedation.
    Koehestanie P; Betzel B; Dogan K; Berends F; Janssen I; Aarts E; Groenen M; Wahab P
    Surg Endosc; 2014 Jan; 28(1):325-30. PubMed ID: 23982649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is reimplantation of the duodenal-jejunal bypass liner feasible?
    Koehestanie P; Betzel B; Aarts EO; Janssen IM; Wahab P; Berends FJ
    Surg Obes Relat Dis; 2015; 11(5):1099-104. PubMed ID: 25979208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial.
    Koehestanie P; de Jonge C; Berends FJ; Janssen IM; Bouvy ND; Greve JW
    Ann Surg; 2014 Dec; 260(6):984-92. PubMed ID: 25072436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation.
    Betzel B; Cooiman MI; Aarts EO; Janssen IMC; Wahab PJ; Groenen MJM; Drenth JPH; Berends FJ
    Surg Endosc; 2020 Jan; 34(1):209-215. PubMed ID: 30877567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis.
    Rohde U; Hedbäck N; Gluud LL; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2016 Mar; 18(3):300-5. PubMed ID: 26537317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity.
    Betzel B; Koehestanie P; Aarts EO; Dogan K; Homan J; Janssen IM; Wahab PJ; Groenen MJ; Berends FJ
    Gastrointest Endosc; 2015 Nov; 82(5):845-52. PubMed ID: 25952090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study.
    Laubner K; Riedel N; Fink K; Holl RW; Welp R; Kempe HP; Lautenbach A; Schlensak M; Stengel R; Eberl T; Dederichs F; Schwacha H; Seufert J; Aberle J
    Diabetes Obes Metab; 2018 Aug; 20(8):1868-1877. PubMed ID: 29569313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duodenal-Jejunal Bypass Liner for the management of Type 2 Diabetes Mellitus and Obesity: A Multicenter Randomized Controlled Trial.
    Ruban A; Miras AD; Glaysher MA; Goldstone AP; Prechtl CG; Johnson N; Chhina N; Al-Najim W; Aldhwayan M; Klimowska-Nassar N; Smith C; Lord J; Li JV; Flores L; Al-Lababidi M; Dimitriadis GK; Patel M; Moore M; Chahal H; Ahmed AR; Cousins J; Aldubaikhi G; Glover B; Falaschetti E; Ashrafian H; Roux CWL; Darzi A; Byrne JP; Teare JP
    Ann Surg; 2022 Mar; 275(3):440-447. PubMed ID: 34647708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The duodenal-jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review.
    Zechmeister-Koss I; Huić M; Fischer S;
    Obes Surg; 2014 Feb; 24(2):310-23. PubMed ID: 24293185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is duodeno-jejunal bypass liner superior to pylorus preserving bariatric surgery in terms of complications and efficacy?
    Balint IB; Csaszar F; Somodi K; Ternyik L; Biro A; Kaposztas Z
    Langenbecks Arch Surg; 2021 Aug; 406(5):1363-1377. PubMed ID: 33712874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study.
    Betzel B; Homan J; Aarts EO; Janssen IMC; de Boer H; Wahab PJ; Groenen MJM; Berends FJ
    Surg Endosc; 2017 Jul; 31(7):2881-2891. PubMed ID: 27804045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner.
    de Moura EG; Martins BC; Lopes GS; Orso IR; de Oliveira SL; Galvão Neto MP; Santo MA; Sakai P; Ramos AC; Garrido Júnior AB; Mancini MC; Halpern A; Cecconello I
    Diabetes Technol Ther; 2012 Feb; 14(2):183-9. PubMed ID: 21932999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine effects of duodenal-jejunal exclusion in obese patients with type 2 diabetes mellitus.
    Kaválková P; Mráz M; Trachta P; Kloučková J; Cinkajzlová A; Lacinová Z; Haluzíková D; Beneš M; Vlasáková Z; Burda V; Novák D; Petr T; Vítek L; Pelikánová T; Haluzík M
    J Endocrinol; 2016 Oct; 231(1):11-22. PubMed ID: 27474690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Effectiveness of an Endoscopically Placed Duodenal-Jejunal Bypass Device (EndoBarrier®): Outcomes in 114 Patients.
    Forner PM; Ramacciotti T; Farey JE; Lord RV
    Obes Surg; 2017 Dec; 27(12):3306-3313. PubMed ID: 29018990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes.
    Jirapinyo P; Haas AV; Thompson CC
    Diabetes Care; 2018 May; 41(5):1106-1115. PubMed ID: 29678867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Early Reimplantation of the Duodenal-Jejunal Bypass Liner Viable?
    Leventi E; Günthert SJ; Stier C; Staikov P; Stein J; Farrag K
    Obes Surg; 2019 May; 29(5):1690-1693. PubMed ID: 30826914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates.
    Gersin KS; Rothstein RI; Rosenthal RJ; Stefanidis D; Deal SE; Kuwada TS; Laycock W; Adrales G; Vassiliou M; Szomstein S; Heller S; Joyce AM; Heiss F; Nepomnayshy D
    Gastrointest Endosc; 2010 May; 71(6):976-82. PubMed ID: 20304396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute pancreatitis as an adverse event in patients with the duodenal-jejunal bypass liner.
    Betzel B; Homan J; Aarts E; Janssen I; Spanier M; Wahab P; Groenen M; Berends F
    Endoscopy; 2015 Nov; 47(11):1050-3. PubMed ID: 26021308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus.
    Glaysher MA; Mohanaruban A; Prechtl CG; Goldstone AP; Miras AD; Lord J; Chhina N; Falaschetti E; Johnson NA; Al-Najim W; Smith C; Li JV; Patel M; Ahmed AR; Moore M; Poulter N; Bloom S; Darzi A; Le Roux C; Byrne JP; Teare JP
    BMJ Open; 2017 Nov; 7(11):e018598. PubMed ID: 29146657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner.
    Riedel N; Laubner K; Lautenbach A; Schön G; Schlensak M; Stengel R; Eberl T; Dederichs F; Aberle J; Seufert J
    Surg Obes Relat Dis; 2018 Jun; 14(6):769-779. PubMed ID: 29650340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.